Panos Kanavos

6PUBLICATIONS
19CO-AUTHORS
Major global burdens of diseaseBusiness information management (incl. records, knowledge and intelligence)Welfare, insurance, disability and social security lawInclusive educationCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 09, 2025
Why drugs fail health technology assessment: a comparative analysis of health technology assessment rejections across seven OECD countries.

Filippos Papadopoulos, Erica Visintin, Ilias Kyriopoulos

|May 15, 2025
A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop.

Hussain Abdulrahman Al-Omar, Asma Abdulaziz Almuhsin, Lolwa Hamad Almudaiyan

|Sep 19, 2024
An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries.

Giovanny Leon, Christophe Carbonel, Aparajit Rampuria

|Dec 15, 2022
Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast].

Panos G Kanavos, Elisabeth Sophia Hartgers-Gubbels, Michael Chambers

|Jul 13, 2022
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.

Daniel Tobias Michaeli, Mackenzie Mills, Panos Kanavos

|Apr 07, 2022
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.

Daniel Tobias Michaeli, Mackenzie Mills, Thomas Michaeli

Pageof 1

Frequent Collaborators

2 joint publications

Daniel Tobias Michaeli

2 joint publications

Mackenzie Mills

1 joint publications

Elisabeth Sophia Hartgers-Gubbels

1 joint publications

Thomas Michaeli